Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Liabilities and Shareholders Equity (2016 - 2025)

Nephros (NEPH) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $13.2 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 27.55% year-over-year to $13.2 million; the TTM value through Sep 2025 reached $48.5 million, up 8.3%, while the annual FY2024 figure was $11.2 million, 5.49% down from the prior year.
  • Liabilities and Shareholders Equity reached $13.2 million in Q3 2025 per NEPH's latest filing, up from $12.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $18.0 million in Q2 2021 and bottomed at $10.4 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $13.1 million, with a median of $11.8 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 37.68% in 2022, then rose 27.55% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $17.6 million in 2021, then tumbled by 37.68% to $11.0 million in 2022, then rose by 7.84% to $11.9 million in 2023, then dropped by 5.49% to $11.2 million in 2024, then rose by 18.17% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $13.2 million in Q3 2025, $12.2 million in Q2 2025, and $11.8 million in Q1 2025.